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Report  1 
A homozygous activating ATAD1 mutation impairs postsynaptic AMPA receptor trafficking 2 
and causes a lethal encephalopathy with congenital stiffness  3 
Running title: ATAD1 and lethal encephalopathy  4 
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Abstract 55 
Members of the AAA+ superfamily of ATPases are involved in the unfolding of proteins and 56 
disassembly of protein complexes and aggregates. ATAD1 encoding the ATPase family, AAA+ 57 
domain containing 1-protein Thorase plays an important role in the function and integrity of 58 
mitochondria and peroxisomes. Postsynaptically, Thorase controls the internalization of 59 
excitatory, glutamatergic AMPA receptors (AMPAR) by disassembling complexes between the 60 
AMPAR-binding protein, GRIP1, and the AMPAR subunit GluA2. Using whole-exome 61 
sequencing, we identified a homozygous frameshift mutation in the last exon of ATAD1 62 
[c.1070_1071delAT; p.(His357Argfs*15)] in three siblings who presented with a severe, lethal 63 
encephalopathy associated with stiffness and arthrogryposis. Biochemical and cellular 64 
analyses show that the C-terminal end of Thorase mutant gained a novel function which 65 
strongly impacts its oligomeric state, reduces stability or expression of a set of Golgi, 66 
peroxisomal and mitochondrial proteins and affects disassembly of GluA2AMPAR and Thorase 67 
oligomer complexes. Atad1-/- neurons expressing Thorase mutantHis357Argfs*15 display reduced 68 
amount of GluA2 at the cell surface suggesting that the Thorase mutant may inhibit the 69 
recycling back and/or reinsertion of AMPARs to the plasma membrane. Taken together, our 70 
molecular and functional analyses identify an activating ATAD1 mutation as a new cause of 71 
severe encephalopathy and congenital stiffness.  72 
Key words: ATAD1, encephalopathy, AMPA receptor trafficking 73 
74 
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Introduction 75 
Early-infantile onset encephalopathies come with an urgent need for a proper diagnosis as 76 
immediate therapeutic decisions have to be made. The majority of these disorders has a 77 
genetic etiology and follows a Mendelian inheritance pattern. Thus, whole-exome sequencing 78 
(WES) is the method of choice to elucidate the related gene in extremely rare forms of early-79 
onset encephalopathies that can lead to early death (Cartault et al., 2012, Kevelam et al., 80 
2013). 81 
The AAA+ family is a large enzymatic group of ATPases associated with various cellular 82 
activities that induce conformational changes in a wide range of substrate proteins. These 83 
ATPases have been involved in various human diseases such as peroxisome biogenesis 84 
disorders, early-onset torsion dystonia linked to DYT1, SPG4- and SPG7-related hereditary 85 
spastic paraplegia and a specific form of inclusion-body myopathy (Hanson and Whiteheart, 86 
2005). One of them, the AAA+ ATPase Thorase encoded by ATAD1 plays a critical role in 87 
regulating the surface-expression of AMPARs (alpha-amino-3-hydroxy-5-methylisoxazole-4-88 
proprionate receptors), thus regulating synaptic plasticity, learning and memory (Ahrens-89 
Nicklas et al., 2017). Here, we report the genotype-phenotype relationship in three infants 90 
exhibiting severe lethal encephalopathy with neonatal stiffness and arthrogryposis resulting 91 
from a homozygous activating ATAD1 mutation. 92 
 93 
Material and Methods 94 
Exome sequencing and sequence data analysis  95 
Written informed consent was received from participants prior to inclusion in the study. 96 
Targeted enrichment and massively parallel sequencing were performed on genomic DNA. 97 
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Enrichment of the whole exome was performed according to the manufacturer’s protocols 98 
using the Nextera Enrichment Kit (62 Mb) (Illumina) for patients 1 and 2 and their mother 99 
(Kortüm et al., 2015). Captured libraries were then loaded onto the 2500 platform (Illumina). 100 
Trimmomatic was employed to remove adapters, low quality (phred quality score < 5) bases 101 
from the 3' ends of sequence reads (Bolger et al., 2014). Reads shorter than 36 bp were 102 
subsequently removed. Further processing was performed following the Genome Analysis 103 
Toolkit's (GATK) best practice recommendations. Briefly, trimmed reads were aligned to the 104 
human reference genome (UCSC GRCh37/hg19) using the Burrows-Wheeler Aligner (BWA 105 
mem v0.7.12). Duplicate reads were marked with Picard tools (v1.141). GATK (v3.4) was 106 
employed for indel realignment, base quality score recalibration, calling variants using the 107 
HaplotypeCaller, joint genotyping, and variant quality score recalibration. AnnoVar (v2015-03-108 
22) was used to functionally annotate and filter alterations against public databases 109 
(dbSNP138, 1000 Genomes Project, and ExAC Browser). Exonic variants and intronic 110 
alterations at exon-intron boundaries ranging from -10 to +10, which were clinically associated 111 
and with allele frequencies <0.5% without homozygous carriers in public databases, were 112 
retained.  113 
 114 
Variant validation  115 
Sequence validation and segregation analysis for all candidate variants were performed by 116 
Sanger-sequencing. Primer pairs designed to amplify selected coding exons and exon-intron 117 
boundaries of candidate genes and PCR conditions are available on request. Amplicons were 118 
directly sequenced using the ABI BigDye Terminator Sequencing Kit (Applied Biosystems) and 119 
an automated capillary sequencer (ABI 3500; Applied Biosystems). Sequence 120 
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electropherograms were analyzed using the Sequence Pilot SeqPatient software (JSI medical 121 
systems).  122 
 123 
RNA isolation, cDNA synthesis and sequencing 124 
Total RNA was extracted (RNeasy Mini kit, Qiagen) from cultured primary fibroblasts obtained 125 
from patient 1 and a control individual. 1 µg total RNA was reverse transcribed (SuperscriptTM 126 
III RT, ThermoFisher) using random hexamers as primers, and 1 μl of the reverse transcription 127 
reaction was utilized to amplify a 669-bp ATAD1 cDNA fragment encompassing the 128 
c.1070_1701delAT variant (forward primer 5′-ATGATGAAAGCTCAGTTTATGAGTC-3′, reverse 129 
primer 5′-GGAACAGTTGAATCCAGCCT-3′). The PCR product was directly sequenced. 130 
 131 
Antibodies and plasmids 132 
All antibodies were acquired commercially: Thorase (mAb, Neuromab, RRID: AB_2564836), 133 
GluA2-N/C (mAb, Millipore-Chemicon, RRID: AB_2113875 and RRID: AB_2247874) and GRIP1 134 
(pAb, Millipore-Chemicon, RRID: AB_11210079), Tomm20, Cox 4, Hexokinase 1, GOS28, PEX26 135 
and VDAC1 (Cell Signaling Tech.), actin-HRP were purchased from GE healthcare (Amersham). 136 
N-Methyl-D-aspartate (NMDA) was purchased from Sigma-Aldrich. Plasmids are described in 137 
“Recombinant protein expression and ATPase activity assays”.  138 
 139 
Protein expression and measurement of oxygen consumption rate in patient cells 140 
Patient-derived and control fibroblast cells were maintained in Dulbecco's Modified Eagle 141 
Medium (DMEM, Corning Cellgro) plus 10% (v/v) bovine serum (FBS) and 1% (v/v) Penicillin-142 
Streptomycin (Corning Cellgro), at 37oC with a 5% CO2 atmosphere in a humidified incubator. 143 
7 
 
Thorase expression and comparative immunoblot analyses were performed using cell lysates 144 
from patient and control fibroblasts. Protein concentrations were determined by BCA protein 145 
assay (PierceTM, Thermo Scientific) and 20 μg were resolved on SDS-PAGE. The immunoblot 146 
membranes were stained with Ponceau stain to assess loading of proteins. Immunoblot 147 
analyses were performed using antibodies to COX 4, Hexokinase 1 (HXK1), PEX26, VDAC1 and 148 
actin (GE Healthcare) as control for loading. Band intensities were quantified using ImageJ 149 
(NIH) and normalized to actin. The values obtained from ImageJ were further analyzed to 150 
determine significant differences using GraphPad Prism software (GraphPad). 151 
The patient-derived and control fibroblast cells cultured on glass coverslips were fixed by 152 
replacing the media with PBS containing 4% PFA and incubated for 10 mins. The cells were 153 
washed three times with PBS and then were permeabilized with 0.5% Triton X-100 in blocking 154 
buffer (5% goat serum in PBS) for 30 mins. The blocking buffer was replaced with PBS 155 
containing Tomm20, GOS28 or PEX26 antibodies (1:1000 dilution) at 4oC overnight. Cells were 156 
washed three times with PBS, and incubated with fluorescent secondary antibodies (Alexa 157 
Fluor 488, Life Technologies) for 2 hr. Coverslips were washed twice follow by 5 mins 158 
incubation with PBS containing DAPI to stain the nuclei and then washed three times with PBS. 159 
The coverslips were mounted on glass slides with Immu-mount (Thermo Scientific) and 160 
imaged using Zeiss LSM Confocal microscope. 161 
Mitochondrial oxygen consumption rate (OCR) was assessed in patient-derived and control 162 
fibroblast cells in an XF24 Extracellular Flux Analyzer (Seahorse Bioscience), as described 163 
previously (Chen et al., 2014). Fibroblast cells (~0.5 X 106 per well) culture media was replaced 164 
with XF24 Dulbecco's Modified Eagle Medium (DMEM) containing 10 mM glucose, 2 mM L-165 
glutamine (Life Technologies) and 2 mM sodium pyruvate (Life Technologies). OCR was 166 
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measured at 37°C with 1-min mix, 1-min wait, and 5-min measurement. The OCR was then 167 
analyzed in the presence of oligomycin, carbonilcyanide m-cholorophenylhydrazone (CCCP) 168 
and rotenone after 30 mins incubation in a CO2 free incubator to assess coupling of respiratory 169 
chain and mitochondrial respiratory capacity. The OCRs were normalized relative to cell 170 
number and basal respiration in each well and is presented as % change. The significant 171 
differences in values obtained were analyzed using GraphPad Prism software (GraphPad). 172 
 173 
3D structure modeling 174 
The C-terminus of Thorase wildtype (Gln259-Asp361) and mutantHis357Argfs*15 (Gln259-Gln370) 175 
was modeled using the SWISS-MODEL (Arnold et al., 2006) and confirmed by Phyre2 (Kelley 176 
et al., 2015) protein modeling, prediction and analysis software. All images obtained were 177 
viewed and labeled with pdb viewer, Pymol. The 3D models are shown as obtained from the 178 
SWISS-MODEL software without any modification. 179 
 180 
Recombinant protein expression and ATPase activity assays 181 
GST-Thorase was generated by cloning the coding sequence of ATAD1 wildtype or 182 
mutantHis357Argfs*15 into pGEX6P1 (GE Healthcare) between BamHI and XhoI. Thorase wildtype 183 
or mutantHis357Argfs*15 coding sequence were also cloned into FUGW (Adgene) between AgeI 184 
and BamHI to generate GFP-tagged Thorase. GST-tagged fusion proteins were expressed in 185 
Escherichia coli strain BL21-CodonPlus (DE3)-RIPL (Stratagene) and purified by using GSTrap 186 
(GE Healthcare), respectively following the manufacturer’s instructions. To obtain non-tagged 187 
Thorase proteins, GST-Thorase bound to beads were treated with PreScission protease (GE 188 
Healthcare) to cleave Thorase from GST. The eluted Thorase was further purified by size 189 
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exclusion chromatography using Superdex 200 10/300GL column (GE Healthcare). The purity 190 
of the recombinant proteins was assessed by SDS-PAGE followed by Coomassie blue staining. 191 
Immunoblotting was used to confirm the presence of proteins in the purified samples. 192 
The ATPase activities of Thorase wildtype and mutantHis357Argfs*15 were assessed by measuring 193 
ATP hydrolysis and [α-32P]-ATP binding. ATP hydrolysis measurements were carried out using 194 
an ADP colorimetric assay kit (BioVision) according to the instructions from the manufacturer. 195 
Approximately, 1.0 mg of purified non-tagged Thorase recombinant proteins were incubated 196 
with 20, 40, 60, 80, 100 and 120 μM ATP in 0.5 ml of ADP assay buffer (supplemented with 2 197 
mM MgCl2) at 37°C for 30 min. The amount of ADP formed due to ATP hydrolysis was then 198 
determined to assess the ATPase activity of Thorase mutantHis357Argfs*15 compared to wildtype. 199 
The ATP binding was evaluated by a photo-labeling technique as described by Babst et al. 200 
(Babst et al., 1998). Approximately 2.0 mg of purified non-tagged Thorase proteins in 0.1 ml 201 
nucleotide binding buffer (50mM Tris.Cl pH 7.5, 150 mM NaCl, 2 mM MgCl2, 5% glycerol) 202 
containing 0.1 mM [α-32P]ATP were incubated at 4oC for 1 hr. The mixtures were exposed to 203 
UV light to cross-link the bound [α-32P]ATP to Thorase, and SDS-PAGE sample buffer was 204 
added to stop the reaction. The samples were resolved on SDS-PAGE, and then exposed to a 205 
phosphor screen (Perkin Elmer). A scanning densitometer was used to quantify the amount of 206 
32P protein labeling in the samples. 207 
 208 
GST-Thorase pull-down of GluA2-GRIP1 complex 209 
For the pull-down assay, purified GST-tagged Thorase proteins immobilized on glutathione 210 
Sepharose beads were incubated with 1 mg of Atad1 knockout whole brain lysates 211 
(homogenized in nucleotide binding buffer with 1% Triton X-100) in the presence of 2 mM 212 
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ADP, ATP or non-hydrolyzable ATPS for two hrs at 4oC followed by 30 mins at 37oC. The beads 213 
were thoroughly washed four times and the bound proteins were eluted in 1X SDS-PAGE 214 
sample loading buffer followed by immunoblot analysis with mouse anti-Thorase, anti-GluA2 215 
and anti-GRIP1 antibodies.  216 
 217 
Thorase oligomer assembling and disassembling assays 218 
Thorase mutantHis357Argfs*15 oligomer formation was evaluated by chemical cross-linking using 219 
glutaraldehyde as previously described (Babst et al., 1998). Approximately 1.0 mg purified 220 
Thorase proteins in nucleotide binding buffer with 2 mM ATP or non-hydrolyzable ATPS were 221 
incubated at 4oC for 2 hrs (to allow oligomer assembling) followed by incubation at 37oC for 222 
30 mins (to allow oligomer disassembling). The cross-linking reaction was stopped by addition 223 
of glycine to a final concentration of 10 mM and samples were mixed with SDS-PAGE sample 224 
loading buffer. The samples were resolved on 4-20% gradient SDS-PAGE (Invitrogen) and 225 
immunoblotted with anti-Thorase antibody to evaluate the presence of Thorase oligomer 226 
complex. 227 
 228 
Surface expression and NMDA-induced endocytosis of GluA2 assays 229 
The effects of the ATAD1 mutation p.(His357Argfs*15) on AMPARs (GluA2) GluA2 (encoded 230 
by GRIA2) surface expression surface were examined in primary cortical neuron cultures 231 
prepared from embryonic day 15 embryos obtained from Atad1 (+/-) x (+/-) breeding as 232 
previously described (Zhang et al., 2011, Prendergast et al., 2014). The neurons were infected 233 
with Thorase-GFP viruses 12 days after plating. To estimate surface GluA2 surface expression 234 
in non-treated (control) and NMDA-induced endocytosis, live neurons were incubated with 2 235 
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mg of mouse-monoclonal anti-N-terminal GluA2 antibodies at 37oC for 1 hr in neuronal growth 236 
media. The neurons were washed twice with fresh growth medium and then replaced with 237 
media containing Tyrodes’ buffer (119 mM NaCl, 5 mM KCl, 25 mM HEPES, 2 mM CaCl2, 2 mM 238 
MgCl2, 1 M TTX + 100 M LY34195) with 20 M CNQX followed by treatment with or without 239 
100 M NMDA for 5 min at 37oC in Tyrodes’ buffer containing 300 M MgCl2 and 10 M 240 
glycine. The media was replaced with 4% paraformaldehyde and 4% sucrose in PBS for 15 mins 241 
to fix the neurons. The neurons were washed three times with PBS followed by treatment with 242 
5% goat serum, 0.3% Triton X-100 in PBS for 1 hr at 4oC and overnight incubation with rabbit-243 
monoclonal anti-C-terminal GluA2 antibody. The neurons were incubated with mouse-Alexa 244 
555-conjugated and rabbit-Alexa 350-conjugated secondary antibodies (Invitrogen) for 2 hrs 245 
after three washes with PBS followed by three washes with PBS before imaging. Images were 246 
acquired by using a Zeiss LSM 710 laser-scanning confocal microscope. The fluorescence 247 
intensities were measured and the internalization index was calculated by intracellular 248 
fluorescence divided by total fluorescence normalized to untreated neurons.  249 
AMPAR surface expression was also evaluated using surface protein-crosslinking assay. 250 
Primary cortical neuron cultures infected with Thorase-GFP viruses treated with/without 251 
NMDA as described above (Zhang et al., 2011, Prendergast et al., 2014). Immediately after 252 
NMDA treatment the medium was replaced with ice-cold artificial cerebrospinal fluid (ACSF) 253 
containing 2 mM membrane-impermeant crosslinking agents, Bis(sulphosuccinimidyl)-254 
suberate [BS3, (Pierce Biotechnology)] (Conrad et al., 2008) to selectively crosslink cell surface 255 
proteins for 30 mins. The reaction was quenched by replacing the BS3 solution with ACSF 256 
containing 0.1 M glycine (with 10 mins incubation) followed by three washes with ACSF 257 
containing 0.1 M glycine. The neurons were suspended in lysis buffer (nucleotide binding 258 
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buffer with 1% triton X-100, and protease inhibitors) and the total protein concentrations 259 
were determined. Equal amount of proteins were resuspended in 1X SDS-PAGE loading buffer, 260 
resolved on 4-12% gradient SDS-PAGE and western immunoblotting were performed to 261 
analyze the surface and intracellular pools of AMPA receptors using anti-GluA2, anti-Thorase 262 
antibodies. 263 
 264 
Data analyses and statistics  265 
All experiments were repeated at least three times and quantitative data are presented as the 266 
mean ± standard error of the mean (SEM) performed by GraphPad prism6 software (Instat, 267 
GraphPad Software). Statistical significance was assessed by one-way ANOVA. The significant 268 
differences were identified by post-hoc analysis using the Tukey-Kramer post-hoc method for 269 
multiple comparisons. Assessments were considered significant with as p<0.05. Power 270 
analysis and sample size calculation for all experiments were determined using G*Power 3.1 271 
statistics software. 272 
 273 
Results and Discussion 274 
Three siblings with severe encephalopathy and a homozygous ATAD1 mutation 275 
The three siblings were born at term by cesarean section for feto-pelvic disproportion with 276 
normal growth parameters. Pregnancies were marked by maternal diabetes. Healthy parents 277 
are first cousins and originated from southern Tunisia. The first patient (subject 1; IV:1; Fig. 278 
1A) was a male who presented at birth with respiratory distress requiring assisted ventilation. 279 
Generalized hypertonia with an exaggerated startle reflex, adducted thumbs, spontaneous 280 
tremor and clonic movements were observed from day 1. EEG showed altered background 281 
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with slow and disorganized activity and multiple multifocal epileptic discharges. Examination 282 
at two months showed major stiffness and distal arthrogryposis with fixed prone position of 283 
upper limbs and bilateral camptodactyly. Deep tendon reflexes were brisk with extensor 284 
plantar reflex. Visual contact was absent and narrow miosis unresponsive to light was noted. 285 
Facial distinctive features including inexpressive facies, anteverted nares, high arched palate 286 
and brachycephaly were observed. Kyphoscoliosis and benign umbilical hernia were also 287 
noted. He had several episodes of pneumonia and died after multiple organ failure at the age 288 
of 5 months. Abdominal ultrasound, eye fundus, spinal cord and brain MRI were normal. 289 
Skeletal X-rays indicated dorsal scoliosis. A large metabolic screening and array CGH did not 290 
show any abnormality. A muscle biopsy was performed and showed focal atrophy of both fiber 291 
types with grouping suggesting an underlying neurogenic disorder. His younger brother 292 
(subject 2; IV:2; Fig. 1A) presented at birth with respiratory distress, poor spontaneous 293 
mobility and no visual contact. Examination showed generalized hypertonia with transient 294 
tremor, bilateral adducted thumbs and clenched toes. He underwent surgery for bilateral 295 
inguinal hernia at 2 months. Regular swallowing difficulties resulted in food misrouting 296 
accidents with subsequent pneumonia. In contrast to his brother, a few intentional smiles 297 
were noted before death, after a novel episode of aspiration pneumonia at the age of 3 298 
months. The ultrasound follow-up of the third pregnancy indicated decreased fetal 299 
movements during the third trimester. The girl (subject 3; IV:3; Fig. 1A) presented at birth with 300 
transient respiratory distress requiring assisted ventilation. In her case, axial hypotonia 301 
contrasted with limb hypertonia. Examination showed poor spontaneous mobility, distal 302 
arthrogryposis with adducted thumbs, ulnar deviation and bilateral clubfoot. Eye contact was 303 
present. She had gastro-esophageal reflux. Brain MRI performed at day 1 showed myelination 304 
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delay and a periventricular white matter hypersignal. EEGs were normal. She died at the age 305 
of 6 months. The common clinical features of the siblings can be summarized as onset of 306 
rigidity at birth, no achievement of developmental milestones and death within the first 307 
months of life. Array CGH and Sanger-sequencing of GLRA1 and SLC6A5 mutated in 308 
hyperekplexia (Tijssen and Rees, 1993, Carta et al., 2012) and SCN4A mutated in congenital 309 
paramyotonia (Koch et al., 1991) did not identify any molecular alteration in the oldest sibling 310 
(patient 1) (data not shown). The severe encephalopathy in the index patient remained thus 311 
unexplained. Next, we performed WES in two affected siblings (subject 1/IV:1 and 3/IV:3) and 312 
their healthy mother (III:3; Fig. 1A, B). Given parental consanguinity, analysis of WES data was 313 
performed according to an autosomal recessive inheritance model. We identified five rare 314 
homozygous variants [with an allele frequency <0.5% in population databases (dbSNP138, 315 
1000 Genomes Project, Exome Variant Server, ExAC and gnomAD browsers) and no 316 
homozygous carriers in the ExAC and gnomAD browsers] shared by the two affected siblings 317 
and present in the heterozygous state in their healthy mother (Supplementary Table 1). 318 
Segregation analysis excluded two of the variants (Supplementary Table 2), while the 319 
remaining variants in RNLS, CDH8 and ATAD1 are not located within a region of significant 320 
homozygosity as assessed by homozygosity mapper (Seelow et al., 2009). However, RNLS and 321 
ATAD1 are located in a homozygous region of ~1.3 Mb on chromosome 10 (data not shown). 322 
In silico pathogenicity assessment and splice-site tools predicted no deleterious effect on 323 
protein function for the missense variant p.(Ile114Val) in RNLS (Supplementary Table 3) and 324 
no pre-mRNA splicing alteration for the synonymous variant c.726T>C in CDH8 325 
(Supplementary Table 4). In contrast, the 2-bp deletion c.1070_1071delAT in the last exon of 326 
ATAD1 was predicted to result in a frameshift with deletion of five amino acids and addition 327 
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of 14 unrelated ATAD1 residues at the C-terminus [p.(His357Argfs*15)], possibly altering 328 
protein function (Fig. 1C, Supplementary Table 3 and Supplementary Fig. 1). The 329 
c.1070_1071delAT variant represents a very rare ATAD1 allele, as it has an allele frequency of 330 
0.00001221 in the gnomAD browser (3 heterozygotes in 245,646 alleles; Supplementary Table 331 
1), in accordance with the rarity of the signs and symptoms presented by the three siblings. 332 
ATAD1 mRNA analysis from patient-derived fibroblasts demonstrated the presence of 333 
transcripts harboring the -2 frameshift at codon 357 and 14 novel codons followed by the stop 334 
codon TGA at their 3’ end (Fig. 1C). This data indicates that mutated ATAD1 mRNAs escape 335 
nonsense-mediated mRNA decay.  336 
ATAD1 encodes the ATPase family, AAA+ domain-containing, member 1, also named 337 
Thorase that is highly expressed in mouse brain and testis (Zhang et al., 2011). Members of 338 
the AAA+ superfamily of ATPases are involved in the unfolding of proteins and disassembly of 339 
protein complexes and aggregates (Hanson and Whiteheart, 2005). In addition, Thorase is able 340 
to maintain mitochondrial function through degradation of mislocalized tail-anchored 341 
proteins to the outer mitochondrial membrane, thus playing an important role in 342 
maintainance of mitochondrial function and integrity (Chen et al., 2014, Okreglak and Walter, 343 
2014). A similar caretaker function of Thorase has also been proposed for peroxisomes 344 
(Grimm et al., 2016). In addition, postsynaptically, Thorase controls the internalization of 345 
excitatory, glutamatergic AMPARs by disassembling complexes between glutamate receptor 346 
interacting protein (GRIP1) and the AMPAR subunit GluA2. Therefore, Thorase deficiency is 347 
expected to impair function of mitochondria and peroxisomes and alter neurotransmission. 348 
Accordingly, Thorase deficiency in mice leads to enhanced AMPAR density at the cell surface 349 
that results in enhanced excitatory postsynaptic currents and impaired adaption to excitatory 350 
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stimuli. Although homozygous Atad1 knockout mice are viable and do not show any obvious 351 
gross malformation, approximately 80% die of a seizure-like syndrome (Zhang et al., 2011). 352 
The C-terminus of Thorase is evolutionarily highly conserved (Supplementary Fig. 1) and 353 
involved in intra- and intermolecular contacts of oligomerized AAA+ ATPase complexes 354 
(Grimm et al., 2016). The ATAD1 mutation identified here causes a deletion of the last five 355 
residues of the C-terminus with addition of 14 novel amino acids (Fig. 1C and Supplementary 356 
Fig. 1). To identify additional ATAD1 variants in individuals with a phenotype similar to that of 357 
the three siblings, two different patient cohorts were studied. First, we analyzed WES datasets 358 
of 2,000 patients with epileptic encephalopathies and hereditary hyperekplexia. Second, 27 359 
cases of glycinergic-negative hyperekplexia with parental consanguinity or atypical 360 
degenerative phenotype with severe developmental outcomes were screened by Sanger-361 
sequencing. No further deleterious variant in ATAD1 emerged from either datasets (data not 362 
shown), suggesting that ATAD1-related congenital encephalopathy with hypertonic stiffness 363 
is an extremely rare condition. 364 
 365 
Altered protein levels but functional mitochondria in fibroblasts from patients with the 366 
ATAD1 mutation p.(His357Argfs*15) 367 
ATAD1 mRNA analysis from patient-derived fibroblasts suggested that the mutated ATAD1 368 
mRNAs produce a protein with an altered C-terminal end. We examined the amount of ATAD1 369 
protein in patient fibroblasts via immunoblotting, which confirmed that the C-terminally 370 
altered ATAD1 mutant is expressed in the patient cells (Fig. 2). Previous studies showed that 371 
the deletion of ATAD1 causes accumulation of peroxisomal biogenesis factor 26 (PEX26) and 372 
Golgi SNARE 28 kDa (GOS28) in human cell lines (Chen et al., 2014). In patient cells expressing 373 
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mutant Thorase, protein level of PEX26 was slightly lower compared to control cells (Fig. 3A, 374 
B), however, we noticed variable expression of this and other proteins in control fibroblast 375 
cells (Fig. 3A, B). In addition, cytochrome c oxidase subunit 4 (COX4), hexokinase 1 (HXK1), and 376 
voltage-dependent anion channel 1 (VDAC1) were also reduced in patient fibroblasts (Fig. 3A, 377 
B). Staining of patient and control cells for GOS28 and PEX26 to evaluate the distribution of 378 
Golgi and peroxisomal proteins, respectively, showed that their levels were decreased in 379 
patient cells when compared to healthy controls (Fig. 3C). Thus, the frameshift mutation in 380 
ATAD1 affects the stability or expression of GOS28 and PEX26. Interestingly, patient 381 
fibroblasts exhibited normal tubular mitochondrial morphology when stained for the 382 
mitochondrial protein TOMM20 (Fig. 3C). The patient fibroblasts also exhibited efficient 383 
mitochondrial respiration (Cooper et al., 2012, Chen et al., 2014), similar to wild-type cells 384 
(Supplementary Fig. 2). These results suggest that the ATAD1 mutation has no significant 385 
effect on mitochondrial function, despite reduction in the level of some mitochondrial 386 
proteins. 387 
 388 
ATAD1 mutation p.(His357Argfs*15) affects the oligomeric state of Thorase but causes no 389 
defects in its ATPase activity  390 
The predicted 3D model of Thorase suggests that the ATAD1 mutation p.(His357Argfs*15) 391 
results in changes in the secondary structure at the C-terminus of Thorase (Fig. 3D). The wild-392 
type C-terminus (Ala349-Asp361) is predicted to form a helix, while in the Thorase 393 
mutantHis357Argfs*15 the helix is shortened and sandwiched by two loops to form a loop-helix-394 
loop (LHL) structure (Fig. 3D). To further examine the activity of the Thorase 395 
mutantHis357Argfs*15, a recombinant expression vector encoding for it was generated. Purified 396 
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wild-type Thorase elutes as 70 kDa (dimer) on a size-exclusion column, while the 397 
mutantHis357Argfs*15 elutes at a higher molecular weight >400 kDa (Fig. 3E). Thus, the 398 
p.(His357Argfs*15) mutation seems to lock the Thorase mutant in an oligomeric state. Both 399 
wildtype and mutant migrated at ~36 kDa in SDS-PAGE as indicated by Coomassie staining and 400 
immunoblot analysis, however, the mutant migrated higher than the wildtype due to the 401 
elongated C-terminus (Fig. 3F). ATP binding assessment using UV light-induced cross-linking 402 
(Harvey et al., 2008) of radiolabeled [α-P32]ATP bound to purified recombinant proteins 403 
suggested that the Thorase mutant binds ATP similar to wildtype (Supplementary Fig. 2). 404 
Similarly, ATP hydrolysis was not significantly affected in the mutant (Supplementary Fig. 2). 405 
These results indicate that the p.(His357Argfs*15) mutation does not affect ATPase activity of 406 
Thorase but strongly impacts its oligomeric state, most likely as a result of the LHL formation 407 
at the C-terminus. 408 
 409 
The Thorase mutantHis357Argfs*15 shows defects in the disassembly of AMPAR-GRIP1 and 410 
Thorase oligomer complexes 411 
Since Thorase regulates AMPAR trafficking (Zhang et al., 2011, Prendergast et al., 2014), we 412 
examined Thorase mutantHis357Argfs*15 interactions with GluA2-GRIP1 complex and particularly 413 
its disassembly. Purified GST-Thorase wildtype and mutant were immobilized on beads and 414 
mixed with Thorase knockout (Atad1-/-) whole brain lysates in the presence of ADP, ATP or 415 
ATPS (Fig. 4A, B, C, D). Both wildtype and mutant bound efficiently to the GluA2-GRIP1 416 
complex in the presence of non-hydrolyzable ATPS, which maintains Thorase in the 417 
oligomeric substrate-bound state (Fig. 4A, B, C). However, in the presence of ATP, which can 418 
be hydrolyzed and is required for the proper disassembly of protein complexes by Thorase, 419 
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wild-type Thorase disassembled the complex, whereas the disassembly was significantly 420 
impaired by the Thorase mutantHis357Argfs*15 (Fig. 4D). These data suggest that the 421 
p.(His357Argfs*15) mutation affects Thorase-mediated AMPAR trafficking, likely by impairing 422 
its transition from oligomeric to monomeric state. The formation of oligomeric complexes by 423 
Thorase and other AAA+ ATPases is critical for their proper assembly and disassembly of 424 
protein complexes (Fujiki et al., 2008). Therefore, we attempted at determining whether the 425 
defect in AMPAR complex disassembly by the mutantHis357Argfs*15 results from improper 426 
Thorase oligomer disassembly. Oligomeric formation and disassembly were evaluated by ATP 427 
binding and glutaraldehyde cross-linking of protein complexes (Babst et al., 1998). Purified 428 
Thorase samples were mixed with ATP (at 4°C to prevent its hydrolysis or at 37°C to allow for 429 
its hydrolysis) or non-hydrolysable ATPS (Supplementary Fig. 2). In the presence of either ATP 430 
at 4°C (ATP-4) or ATPS Thorase formed large oligomeric complexes of molecular weights 431 
greater than 250 kDa (Supplementary Fig. 2). While 71 ± 4.7% of Thorase wildtype formed 432 
oligomers, 89 ± 6.3% of the mutants were found in the oligomeric state (ATP-4 in 433 
Supplementary Fig 2). Upon ATP hydrolysis (ATP-37), 75.5 ± 4.4% of Thorase wildtype and 57.6 434 
± 7.6% of mutant disassembled oligomeric complexes (Supplementary Fig. 2). These results 435 
indicate and further confirm that the p.(His357Argfs*15) mutation impairs normal 436 
disassembly of Thorase oligomers. Although we observed a defect of 14-18% in oligomeric 437 
disassembly in the Thorase mutantHis357Argfs*15 compared to wildtype, this may be significant 438 
enough to cause severe consequences in terms of clinical phenotype. 439 
 440 
Atad1-/- neurons expressing the Thorase mutantHis357Argfs*15 display reduced GluA2 surface 441 
expression 442 
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Since Thorase regulates surface expression of AMPARs the effects of the p.(His357Argfs*15) 443 
mutation on AMPARs trafficking was evaluated. An antibody-feeding assay for endocytosis of 444 
surface GluA2 receptors (Zhang et al., 2011, Prendergast et al., 2014) was performed in Atad1-445 
/- primary cortical neurons expressing GFP-tagged Thorase wildtype or mutantHis357Argfs*15. Live 446 
neurons were incubated with an anti-GluA2 N-terminal antibody followed by induction of 447 
GluA2 endocytosis with N-methyl-D-aspartate (NMDA) (20 µM) and glycine (10 µM). In control 448 
unstimulated Thorase mutantHis357Argfs*15 cultures there was decreased surface expression of 449 
GluA2 compared to Thorase wildtype cultures (Fig. 4E, F). In contrast, the ratio of surface 450 
GluA2/intracellular GluA2 in NMDA- and glycine-stimulated Thorase mutant cortical cultures 451 
remained similar to that of stimulated Thorase wildtype cultures (Fig. 4G, H). Thus, the 452 
mutantHis357Argfs*15-expressing neurons exhibited significantly reduced surface GluA2 only 453 
under unstimulated conditions. To further evaluate the effects of the p.(His357Argfs*15) 454 
mutation in Thorase on AMPAR trafficking, GluA2 surface expression was assessed by a 455 
bis(sulfosuccinimidyl)-suberate (BS3) cross-linking assay that allows for the quantification of 456 
both surface and intracellular receptor pools (Conrad et al., 2008). The results suggested 457 
decreased levels of surface GluA2 in unstimulated mutantHis357Argfs*15-expressing cultures 458 
compared to wildtype-expressing cultures (Fig. 4I, J). In response to NMDA, there was no 459 
significant difference in internalization of surface GluA2 in the two cultures (Fig. 4I, J). 460 
Together, the data suggest that the Thorase mutantHis357Argfs*15 may inhibit the recycling back 461 
and/or reinsertion of AMPARs to the surface following endocytosis resulting in a decrease in 462 
the steady-state levels of these receptors at the cell surface. 463 
 Taken together, these results demonstrate that a homozygous frameshift mutation at 464 
the 3’ end of ATAD1 leads to the production of Thorase protein with a novel function of its C-465 
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terminal end. Interestingly, through a gain-of-function effect, an unusual mechanism in 466 
autosomal recessive disease, the ATAD1 mutation causes a congenital severe and lethal 467 
encephalopathy associated with stiffness and arthrogryposis. Previously, we reported a 468 
homozygous loss-of-function mutation (p.Glu276*) in ATAD1 that underlies a neurological 469 
disorder with remarkable clinical overlap to the phenotype reported here: patients showed 470 
hypertonia, seizures, respiratory failure and early death (Ahrens-Nicklas et al., 2017). In the 471 
affected neonates, movement was precluded due to extreme hypertonia. Thus, stiffness was 472 
common to both families (this report and (Ahrens-Nicklas et al., 2017)), while clinical seizures 473 
starting at birth were only present in infants with ATAD1 nonsense mutation (Ahrens-Nicklas 474 
et al., 2017). Given that different ATAD1 mutations have been identified in two separate 475 
families with critical neurological phenotypes in neonates, ATAD1 can be considered as an 476 
important human disease gene. Our functional assays showed deficiency in AMPAR recycling 477 
as the molecular mechanism associated with the disease. The gain-of-function mutation in 478 
ATAD1 decreases the population of excitatory postsynaptic AMPA receptors. However, 479 
mitochondrial function does not seem to be affected by the ATAD1 p.(His357Argfs*15) 480 
mutation as patient-derived fibroblasts show normal mitochondrial morphology and 481 
respiratory chain performance. In contrast, Atad1 loss-of-function causes a decrease of many 482 
mitochondrial proteins in mouse brain in which the Golgi protein GOS28 ectopically 483 
accumulated. In addition, Atad1-deficient mouse embryonic fibroblasts show decreased basal 484 
and mitochondrial respiration, severely fragmented mitochondria and mislocalization of 485 
GOS28 and PEX26 in mitochondria suggesting significant mitochondrial impairment in this 486 
mouse mutant (Chen et al., 2014). These findings together with impaired AMPAR 487 
internalization resulting in increased GluA1 and GluA2 surface levels in Atad1 knockout 488 
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neurons suggest a combined effect of defects in both AMPAR trafficking and mitochondrial 489 
function that might have contributed to the phenotype in Atad1-/- mice (Zhang et al., 2011, 490 
Chen et al., 2014). Similarly, we speculate that the distinct combination of functional 491 
alterations arising from either gain- or loss-of-function ATAD1 mutations may provide an 492 
explanation for the discrete although overlapping phenotypes observed in the siblings 493 
reported here and the previously described family.  494 
 Changes in AMPAR receptor surface expression is a known pathogenic mechanism in 495 
encephalopathy; for example, a decrease in extrasynaptic AMPAR expression impairs synaptic 496 
plasticity in a model of hepatic encephalopathy (Schroeter et al., 2015). This disrupts the 497 
efficacy of synaptic transmission and the fine balance between inhibitory and excitatory 498 
signaling, which accounts, at least partially, for the encephalopathy. There are additional 499 
possible targets of Thorase that contribute to the encephalopathy and neurologic phenotype 500 
of patients with mutations in ATAD1. Consistent with this notion is the observation that the 501 
AMPAR antagonist, perampanel, only partially rescued the phenotype of patients with a loss-502 
of-function mutation in ATAD1 (Ahrens-Nicklas et al., 2017). The findings from our study 503 
establish an important avenue for clinicians to examine the role of ATAD1 mutations in several 504 
neurological diseases due to unknown cause. 505 
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 575 
Figure legends 576 
Figure 1 DNA and RNA analysis in the family with three siblings carrying the homozygous 577 
ATAD1 mutation. (A) Pedigree of the family. (B) Partial sequence electropherograms 578 
demonstrating the ATAD1 c.1070_1071delAT [p.(His357Argfs*15)] mutation in the 579 
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homozygous state in leukocyte-derived DNA of the affected siblings (Subjects 1, 2 and 3). Their 580 
healthy parents (Father and Mother) are heterozygous carriers of the mutation. (C) Partial 581 
sequence electropherograms show the 2-bp deletion in ATAD1 in fibroblast-derived cDNA of 582 
one sibling (Mutant) in comparison to the cDNA sequence of a healthy individual (Wild-type). 583 
Deleted bases are marked by parenthesis in the normal sequence. The encoded amino acid 584 
residues are depicted below each sequence in the three-letter code and show the 14 novel 585 
amino acid residues at the C-terminus of ATAD1 (highlighted in bold). *: stop codon. 586 
 587 
Figure 2 Mutant Thorase is expressed in patient-derived fibroblasts. (A) Immunoblot of lysates 588 
obtained from patient and control fibroblasts. Expression of Thorase was monitored by using 589 
anti-Thorase antibody, and anti-actin antibody was used to control for equal loading. As the 590 
anti-Thorase antibody was generated against the C-terminus and this region contains a new 591 
amino acid composition in the mutant, detection of Thorase in patient cells was difficult 592 
(compare the clear band in control and the diffuse band in patient cells). (B) Optical 593 
densitometry quantification of (A). Values represent the mean±SEM (n=3, n.s. p>0.05, Tukey’s 594 
multiple comparison tests). 595 
 596 
Figure 3 The ATAD1 mutation p.(His357Argfs*15) leads to reduced amount of some 597 
mitochondrial proteins in patient-derived fibroblasts and locks Thorase in the oligomeric state. 598 
(A) Immunoblots of lysates obtained from patient and control fibroblasts. COX1, cytochrome 599 
c oxidase subunit 1; HXK1, hexokinase 1; PEX26, peroxisomal biogenesis factor 26; VDAC1, 600 
voltage dependent anion channel 1. (B) Optical densitometry quantification of (A). Values 601 
represent the mean+SEM (n=3, n.s. p>0.05, * p<0.05, two-way ANOVA, Tukey’s multiple 602 
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comparison tests). (C) Representative immunofluorescence images of the mitochondrial 603 
morphology (TOMM20 staining) in control and patient fibroblasts. The cells were also stained 604 
for Golgi (GOS28), peroxisomes (PEX26) and the nuclei with DAPI (blue). (D) Predicted 3D 605 
structure of Thorase wildtype (green) and mutantHis357Argfs*15 (red). (E) Size exclusive 606 
chromatograph profile of purified recombinant Thorase. Wild-type Thorase appears as a 607 
dimer (~70 kDa), whereas the Thorase mutantHis357Argfs*15 appears as oligomer (>400 kDa). (F) 608 
Purified proteins resolved on 10% SDS-PAGE stained with coomassie (left) and immunoblotted 609 
with anti-Thorase antibody (right). 610 
 611 
Figure 4 ATAD1 mutation p.(His357Argfs*15) affects GluA2-GRIP1 complex disassembly and 612 
GluA2 surface expression. (A) Immunoblot analyses of GST-Thorase pulldown of the GluA2-613 
GRIP1 complex from Thorase knockout whole brain lysate in the presence of different 614 
nucleotides (ADP, hydrolysable ATP; ATPγS, non-hydrolysable ATP). The samples were 615 
incubated at 4oC for binding and then at 37oC for ATP hydrolysis to trigger the disassembly of 616 
the protein complex. (B-C) The graphs represent normalized percent bound GluA2 (B) and 617 
GRIP1 (C) in the GST-Thorase pulldown samples for (A). (D) Normalized percentage of GluA2 618 
and GRIP1 disassembled from Thorase-GluA2-GRIP1 complex in (A). (E-F) Representative 619 
immunofluorescence images of unstimulated and NMDA-induced endocytosis of GluA2 in 620 
Atad1-/- neurons expressing Thorase-GFP wildtype (WT) or the mutantHis357Argfs*15 (Mutant). (G) 621 
Normalized ratio of surface GluA2 (sGluA2) to internalized GluA2 (iGluA2) for (E-F). (H) GluA2 622 
internalization index measured as the ratio of iGluA2 to the total GluA2 (iGluA2 plus sGluA2) 623 
fluorescence intensities. (I) Immunoblot analyses of BS3-crosslinking of sGluA2 in Atad1-/- 624 
neurons expressing Thorase-GFP wildtype or mutantHis357Argfs*15. (J) The normalized optical 625 
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densitometry quantification of sGluA2 for (I). (mean±SEM of three experiments performed in 626 
triplicate. n=3, ** p<0.05, * p<0.10, n.s p>0.10, ANOVA with Tukey-Kramer post-hoc test when 627 
compared with wildtype).  628 
